PharVision Advisers’s TD Synnex SNX Stock Holding History

PharVision Advisers’s Portfolio SNX Stock Details SNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,797	Closed	-$270K	–	566
2025 Q4	$270K	Buy	+1,797	New	+$276K	0.14%	340

Other funds holding SNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BWA

Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ABI

Abrams Bison Investments Bethesda, Maryland $2.31B AUM 40.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

PharVision Advisers's SNX Position: Q1 2026 in Review

PharVision Advisers sold out of TD Synnex (SNX) in Q1 2026, closing a stake of 1,797 shares — an estimated $270K sold.

PharVision Advisers first reported a position in SNX in Q4 2025 and held it in 1 quarter. The position peaked at $270K in Q4 2025. 603 funds tracked by Wall St. Rank hold SNX as of Q1 2026.

PharVision Advisers reported no remaining TD Synnex position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,797 TD Synnex shares in Q1 2026, an estimated $270K.
PharVision Advisers first reported a position in TD Synnex in Q4 2025 and held it in 1 quarter.
PharVision Advisers's TD Synnex position peaked at $270K in Q4 2025.
603 funds tracked by Wall St. Rank held TD Synnex as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.